Deletions of chromosome 6q27 are associated at high frequency with various common tumor types including non-Hodgkin lymphoma (NHL;>20%), ovarian carcinoma (>70%), and breast carcinoma (approximately 50%). Loss of heterozygosity (LOH), radiation-hybrid mapping and cloning studies have identified a minimal region of loss within 6q27 common to all NHL cases and, within this region, a 60kb subregion containing the minimal regions of loss in breast and ovarian carcinoma. These associations suggest that 6q27 may contain a tumor suppressor gene (DOBL; deleted in ovarian, breast carcinoma and lymphoma) altered in multiple cancer types. The goal of this project is to identify the DOBL gene and to elucidate the role of its alterations in tumorigenesis. The following specific aims will be pursued: 1) Identification of the DOBL gene by mutation analysis of genes mapping within the 60 kb minimal deletion region in breast carcinoma cases carrying heterozygous deletions or wild-type 6q27 regions. 2. Screening ovarian carcinoma, NHL and other tumors for DOBL mutations in order to determine whether the same suppressor gene is involved in 6q27 deletions in different tumor types. 3. Characterization of the structure and pattern of expression of the DOBL gene product by determining it structural organization and homology to known proteins, its subcellular localization and its pattern of expression during development, tissue proliferation and differentiation. 4. Characterization of the biological function of the DOBL gene, including the analysis of its tumor suppressor activity in transfected cell lines in vitro, and its disruption in the mouse germ-line to determine its role on tissue-development and tumorigenesis in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA075553-01A1
Application #
6269864
Study Section
Project Start
1998-07-15
Project End
1999-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Politi, Katerina; Szabolcs, Matthias; Fisher, Peter et al. (2004) A mouse model of uterine leiomyosarcoma. Am J Pathol 164:325-36
Politi, Katerina; Kljuic, Ana; Szabolcs, Matthias et al. (2004) 'Designer' tumors in mice. Oncogene 23:1558-65
Mason, Jeffrey L; Xuan, Shouhong; Dragatsis, Ioannis et al. (2003) Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci 23:7710-8
Chiao, Eric; Fisher, Peter; Crisponi, Laura et al. (2002) Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol 243:185-206
Zhang, Mei; Xuan, Shouhong; Bouxsein, Mary L et al. (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-12
Podsypanina, K; Lee, R T; Politis, C et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-5
Ludwig, T; Fisher, P; Ganesan, S et al. (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 15:1188-93
Simpson, L; Li, J; Liaw, D et al. (2001) PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol Cell Biol 21:3947-58
Ludwig, T; Fisher, P; Murty, V et al. (2001) Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20:3937-48
Dietrich, P; Dragatsis, I; Xuan, S et al. (2000) Conditional mutagenesis in mice with heat shock promoter-driven cre transgenes. Mamm Genome 11:196-205

Showing the most recent 10 out of 13 publications